Merck presented pivotal data showing its oral PCSK9 candidate produced LDL-cholesterol reductions comparable to injectable PCSK9 inhibitors. In analyses reported at the American Heart Association, the CORALreef Lipids trial and a HeFH cohort showed LDL reductions near 59–60% versus placebo at 24 weeks after a post-hoc re-analysis to correct baseline data anomalies. Market analysts flagged the drug’s oral route, room-temperature stability and potential lower cost as factors that could accelerate uptake in primary care. Merck disclosed the re-analysis steps and emphasized the robustness of the corrected result; the data set positions the program as a potential alternative to Amgen and Regeneron biologics if regulators concur.